AbCellera Biologics Inc

Research AbCellera Biologics Inc (ABCL) on Bullrun: market cap USD 2.48B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerABCL
• ExchangeNASDAQ
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.48B
• Financial periodFY2025
• RevenueUSD 75.13M
• Revenue growth160.6%
• Net income-USD 146.41M
• Free cash flow-USD 174.07M

Valuation Snapshot

latest market cap is USD 2.48B.

About AbCellera Biologics Inc

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.

Frequently asked questions

What is AbCellera Biologics Inc's market cap?

AbCellera Biologics Inc's market capitalization is USD 2.48B.

What does AbCellera Biologics Inc do?

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms;